Journal
CURRENT OPINION IN VIROLOGY
Volume 2, Issue 4, Pages 482-488Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coviro.2012.06.005
Keywords
-
Categories
Funding
- National Institute of Health [CA91791, DE14153, DE15752]
- UCLA Center for AIDS Research (CFAR) NIH/NIAID [AI028697]
- UCLA Jonsson Comprehensive Cancer Center (JCCC) NIH/NCA [P30 CA016042]
- National Basic Research Program of China [2011CB504803, 2011CB504305]
Ask authors/readers for more resources
Infection of Kaposi sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8) is estimated to account for 34,000 new cancer cases globally. Unlike other herpesviruses, KSHV is not ubiquitous but is highly prevalent in some areas, such as sub-Saharan Africa where Kaposi sarcoma is the leading cancer among adults. While latent infection of KSHV plays a major and direct role in tumorigenesis, viral lytic replication also makes significant contributions to this process. Efforts to develop a KSHV vaccine are limited, but studies with EBV have provided important lessons. Informative vaccine research has been conducted in the mouse infection model of a closely related rodent virus, murine gammaherpesvirus-68 (MHV-68 or gamma HV-68). This mouse model has generated fundamental principles for an effective vaccination strategy. KSHV vaccines designed to prevent a naive host from infection and to boost the immune control of KSHV in persistently infected people will have major impact on individuals who are at a high risk of developing KSHV-associated diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available